推薦產品
等級
pharmaceutical primary standard
API 家族
probenecid
製造商／商標名
USP
應用
pharmaceutical (small molecule)
形式
neat
SMILES 字串
CCCN(CCC)S(=O)(=O)c1ccc(cc1)C(O)=O
InChI
1S/C13H19NO4S/c1-3-9-14(10-4-2)19(17,18)12-7-5-11(6-8-12)13(15)16/h5-8H,3-4,9-10H2,1-2H3,(H,15,16)
InChI 密鑰
DBABZHXKTCFAPX-UHFFFAOYSA-N
基因資訊
human ... SLC22A11(55867) , SLC22A6(9356) , SLC22A8(9376)
尋找類似的產品？ 前往 產品比較指南
一般說明
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
應用
Probenecid USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:
- Probenecid and Colchicine Tablets
- Probenecid Tablets
分析報告
These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.
其他說明
Sales restrictions may apply.
訊號詞
Warning
危險聲明
危險分類
Acute Tox. 4 Oral
儲存類別代碼
11 - Combustible Solids
水污染物質分類（WGK）
WGK 3
閃點（°F）
Not applicable
閃點（°C）
Not applicable
Probenecid and zidovudine metabolism.
Kornhauser, DavidM, et al.
Lancet, 334.8661, 473-475 (1989)
Clinical pharmacokinetics of probenecid.
Cunningham, R. F., Z. H. Israili, and P. G. Dayton.
Clinical Pharmacokinetics, 6.2, 135-151 (1981)
Nathan Robbins et al.
Cardiovascular toxicology, 12(1), 1-9 (2011-09-23)
Probenecid was initially developed with the goal of reducing the renal excretion of antibiotics, specifically penicillin. It is still used for its uricosuric properties in the treatment in gout, but its clinical relevance has sharply fallen and is rarely used
G R Brown
Clinical pharmacokinetics, 24(4), 289-300 (1993-04-01)
The effect of concurrent probenecid administration on the pharmacokinetics of cephalosporin antibiotics varies with the available cephalosporins. Most cephalosporins are affected to some degree by concurrent probenecid administration, although ceforanide, ceftazidime, ceftriaxone and latamoxef (moxalactam) have no significant changes in
R W Cowdry et al.
Biological psychiatry, 18(11), 1287-1299 (1983-11-01)
Probenecid is used to block the transport of acid monoamine metabolites from cerebrospinal fluid (CSF), on the assumption that the resultant rise in CSF concentrations of the metabolites will reflect presynaptic "turnover" of the parent monoamine. However, CSF levels of
我們的科學家團隊在所有研究領域都有豐富的經驗，包括生命科學、材料科學、化學合成、色譜、分析等.
聯絡技術服務